{
  "id": 4891319,
  "title": "EFHD1 may turn fatty liver disease into injury, with inhibition reducing scarring by up to 60%",
  "url": "https://urgent.news/2026/09/01/efhd1-may-turn-fatty-liver-disease-into-injury-with-inhibition",
  "topic": "science",
  "section": "Science",
  "published": "2026-09-01T16:00:12.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-efhd1-fatty-liver-disease-injury.html"
  },
  "original_language": "en",
  "account": "Obesity-related liver disease affects millions, but not all livers progress to scarring and failure. Researchers at the University of Utah discovered a protein, EFHD1, that may trigger this progression. EFHD1 activates an antiviral immune response in mitochondria, which can damage the liver. Inhibiting EFHD1 reduces liver damage by up to 60%, even in high-fat diet conditions. This finding could lead to new therapies to prevent liver injury.",
  "summary": "Obesity-related metabolic liver disease affects hundreds of millions of people worldwide, but only some of those livers develop scarring, become inflamed and eventually fail. University of Utah researchers have identified a protein, EFHD1, that appears to drive that transition by triggering an out-of-place antiviral immune response.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}